Milestone Pharmaceuticals Inc.
1111 Dr. Frederik-Philips Boulevard, Suite 420
Montréal, Québec CA H4M 2X6

 

VIA EDGAR

 

November 20, 2024

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attn:

Chris Edwards

 

Re:	Milestone Pharmaceuticals Inc.
	Registration Statement on Form S-3 File No. 333-283162
	Acceleration Request
	Requested Date:	Friday, November 22, 2024
	Requested Time:	4:00 P.M. Eastern Time

 

Ladies and Gentlemen:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-283162) (the “Registration Statement”) to become effective on Friday, November 22, 2024, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the Staff.

 

The Registrant hereby authorizes each of Ryan S. Sansom and Sarah E. Curry of Cooley LLP to make such request on its behalf.

 

Once the Registration Statement has been declared effective, please orally confirm that event with Sarah E. Curry of Cooley LLP, counsel to the undersigned registrant, at (212) 479-6652.

 

[Signature Page Follows]

 

 

Sincerely,
Milestone Pharmaceuticals Inc.
By:	/s/ Joseph Oliveto
	Joseph Oliveto
	Chief Executive Officer

 

cc:	Amit Hasija, Milestone Pharmaceuticals Inc. Ryan S. Sansom, Cooley LLP Sarah E. Curry, Cooley LLP